Business Context and Reporting Period
This Form 6-K filing by MediWound Ltd. covers the month of December 2022, with a specific announcement date of December 5, 2022. The filing details a corporate action regarding the Company's capital structure rather than operational performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the mechanics of a reverse share split.
Material Changes
- Reverse Share Split: The Board of Directors approved a 7:1 reverse split of ordinary shares, effective December 20, 2022, subject to Nasdaq requirements.
- Share Conversion: Every seven issued and outstanding shares will be converted into one share. Fractional shares will be rounded up to the next whole number.
- Authorized Capital Adjustment: The authorized number of ordinary shares will be reduced from 90,000,000 to 12,857,143.
- Par Value Increase: The par value per share will increase from NIS 0.01 to NIS 0.07 to maintain the overall authorized share capital.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on future business performance. The rationale for the split and potential investment impacts are referenced in a prior proxy statement (Exhibit 99.1 to a Form 6-K filed on October 21, 2022) rather than detailed in this text. The primary contingency noted is the satisfaction of Nasdaq Operations notice requirements for the split to become effective.
Investor Verification Checklist
- Confirm the effective date of the 7:1 reverse split (December 20, 2022) and the start of trading on a split-adjusted basis.
- Verify the treatment of fractional shares (rounded up to the next whole number).
- Check the updated authorized share count (12,857,143) and par value (NIS 0.07) in subsequent filings.
- Review the referenced October 21, 2022, proxy statement for the detailed rationale behind the split.